Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amy Moeller

Family Medicine Perkasie, PA Doctor of Osteopathy

NPI 1912951310 CMS profile 313373

1301 N 5Th St, Perkasie, PA 18944

Open in the dashboard

General payments

$3,358

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Moeller of Perkasie, PA is reported in the CMS Open Payments database as having received $3,358 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $674 30
2024 General $595 27
2023 General $500 25
2022 General $114 5
2021 General $203 10
2020 General $244 15
2019 General $1,028 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Moeller
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Amy Moeller were reported at $674. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Amy Moeller Family Medicine median Middle half National median
2019 $1,028 $150 $41–$543 $163
2020 $244 $120 $32–$415 $114
2021 $203 $137 $35–$551 $132
2022 $114 $137 $37–$512 $149
2023 $500 $149 $42–$545 $160
2024 $595 $156 $44–$560 $164
2025 $674 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $505 29 payments
  2. AstraZeneca Pharmaceuticals LP $492 27 payments
  3. Astellas Pharma US Inc $448 21 payments
  4. AbbVie, Inc. $404 17 payments
  5. Pfizer Inc. $341 18 payments
  6. Merck Sharp & Dohme Corporation $196 13 payments
  7. Lilly USA, LLC $192 8 payments
  8. Janssen Pharmaceuticals, Inc $140 11 payments
  9. Medtronic Vascular, Inc. $125 1 payment
  10. Amgen Inc. $108 6 payments
  11. Other $407 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,317 172 payments
  2. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $371 18 payments
  2. FARXIGA $296 16 payments
  3. QULIPTA $284 12 payments
  4. UBRELVY $281 12 payments
  5. Ozempic $247 14 payments
  6. STEGLATRO $196 13 payments
  7. MOUNJARO $192 8 payments
  8. BELSOMRA $157 10 payments
  9. JANUVIA $156 11 payments
  10. INVOKANA $140 11 payments
  11. Other $2,726 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

7,946

Median for Family Practice: 1,826

Drug cost

$440,844

Median for Family Practice: $120,094

Branded share of claims

16.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 77 $61,586
Eliquis Apixaban Brand 86 $55,460
Mounjaro Tirzepatide Brand 51 $52,034
Myrbetriq Mirabegron Brand 56 $26,926
Creon Lipase/Protease/Amylase Brand 17 $22,177
Synjardy Xr Empagliflozin/Metformin Hcl Brand 17 $18,446
Prevacid Lansoprazole Brand 28 $16,425
Januvia Sitagliptin Phosphate Brand 22 $15,375
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $12,647
Ozempic Semaglutide Brand 14 $12,325

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$82,898

Of which drugs: $20,939

Medicare patients

409

Average age 76

Services billed

2,264

270 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 36%
Diabetes 22%
Ischemic heart disease 22%
Chronic kidney disease 22%
Depression 20%
Osteoporosis 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 126 129 $10,433
Sarscv2 vac 30mcg trs-suc im 91320 Office 34 35 $5,151
Pcv20 vaccine im 90677 Office 17 17 $4,929

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $56
$56 51 —
Veozah
  • Astellas Pharma US Inc $51
$51 — —
VRAYLAR
  • AbbVie, Inc. $49
$49 — —
UBRELVY
  • AbbVie, Inc. $48
$48 — —
QULIPTA
  • AbbVie, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record